Tris Pharma To Pay Texas $7.5 Million Over Alleged Misleading ADHD Drug Claims
Dallas Express
Tris Pharma has agreed to pay Texas $7.5 million to settle allegations that it made misleading claims about the effectiveness of its ADHD medication, Dyanavel XR, marketed to children. The settlement resolves claims that the company overstated the drug's benefits and misled Texas Medicaid providers through sales representatives. The agreement does not admit guilt, but acknowledges disputed facts and aims to avoid prolonged litigation.
All articles from 2 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.